clinical trial · NCT06005974
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
AXIN1 Gene MutationAPC Gene MutationSolid TumorREC-4881
brief summary
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.
started
Jan 15, 2024
primary completion
Feb 24, 2025
completion
Feb 24, 2025
last updated
Feb 23, 2026
official title
A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol